1) Guan W.-j., Ni Z.-y., Hu Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. APR 30, 2020. N Engl J Med 2020; 382:1708-1720
2) BMJ BEST PRACTISE. Enfermedad de Coronavirus 2019 (COVID-19). Última actualización: May 13, 2020. https://bestpractice.bmj.com/topics/es-es/3000168/pdf/3000168/Enfermedad%20de%20coronavirus%202019%20%28COVID-19%29.pdf. (Consultado el 14/5/2020)
3) Fei Zhou, Ting Yu, Ronghui Du, et. al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. Volume 395, Issue 10229, 28 March–3 April 2020, Pages 1054-1062.
4) Waleed Alhazzani, Morten HylanderMøller, Yaseen M. Arabi, et. al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) European Society of Intensive Care Medicine and the Society of Critical Care Medicine 2020. DOI: 10.1007/s00134-020-06022-5.
5) Australian Government Departure of Health. CDNA National Guidelines for Public Health Units. Coronavirus Disease 2019 (COVID-19). 1 May 2020. Communicable diseases network. Australia.
6) Ying-Hui Jin, Lin Cai, Zhen-Shun Cheng et. al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Medical Research. (2020) 7:4. https://doi.org/10.1186/s40779-020-0233-6.
7) Jiang, Shibo y col. “Dominios de unión al receptor de proteínas espiga de virus emergentes o reemergentes como objetivos para el desarrollo de vacunas antivirales”. Microbios e infecciones emergentes vol. 1,8 (2012): e13. doi: 10.1038 / emi.2012.1
8) Jeffrey K Aronson, Robin E Ferner. ACE inhibitors and angiotensin receptor blockers (ARBs) COVID-19? 22 de marzo del 2020. BMJ 2020;369:m1313.
9) Jan Danser , Murray Epstein, Daniel Batlle. Renin-Angiotensin System Blockers and the COVID-19 Pandemic. https://doi.org/10.1161/HYPERTENSIONAHA.120.15082Hypertension.
10) HaticeGumushan-Aktas, SeyhanAltun. Effects of Hedera helix L. extracts on rat prostate cancer cell proliferation and motility. Oncol Lett. 2016 Oct; 12(4): 2985–2991. Published online 2016 Aug 3. doi: 10.3892/ol.2016.4941
11) Ministry of Health. COVID-19 Reference Document for Symptoms. – April 22, 2020. Version 1.0. Ontario.
12) David A. Berlin, M.D., Roy M. Gulick, M.D., M.P.H., and Fernando J. Martinez, M.D.Severe Covid-19. Clinicalpractice. NEJM. May 15, 2020. DOI: 10.1056/NEJMcp2009575
13) Una clasificación que cambia la práctica. Neumonía COVID-19: ¿Diferentes tratamientos para diferentes fenotipos? 17 de Abril de 2020. Intramedhttps://www.intramed.net/95973 . Consultado el 14/05/2020 (16 hs).
14) Vademecum colombiano de plantas medicinales. Ministerio de la Protección Social. PMCID: PMC5038493 Pag. 149- 50. Año 2008. Bogotá.
https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/SA/vademecum-colombiano-plantas-medicinales.pdf
15) Hofmann D, Hecker M, Völp A. Efficacy of dry extract of ivy leaves in children with bronchial asthma–a review of randomized controlled trials. Phytomedicine. 2003;10(2-3):213‐220. doi:10.1078/094471103321659979
16) Ali Esmail Al-Snafi. Pharmacological and therapeutic activities of Hedera helix- A review. IOSR Journal Of Pharmacy. Volume 8, Issue 5 Version. PP. 41-53. May 2018.
17) Brurberg KG, Fretheim A. Aerosol generating procedures in health care, and COVID-19. Rapid review 2020. Oslo: Norwegian Institute of Public Health, 2020.
18) Hong EH, Song JH, Shim A, et al. Coadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with Oseltamivir. PLoS One.
2015;10(6):e0131089. Published 2015 Jun 22. doi:10.1371/journal.pone.0131089
19) Schulte-Michels, J., Keksel, C., Häberlein, H. et al. Anti-inflammatory effects of ivy leaves dry extract: influence on transcriptional activity of NFκB. Inflammopharmacol 27, 339–347 (2019). https://doi.org/10.1007/s10787-018-0494-9
20) Büechi S, Vögelin R, Mennet-von Eiff M y colaboradores. ForschendeKomplementärmedizin und KlassischeNaturheilkunde Open Trial to Assess Aspects of Safety and Efficacy of a Combined Herbal Cough Syrup with Ivy and Thyme 12(6):328-332, Dic 2005. Revisado a traves de Intramed: https://www.intramed.net/contenidover.asp?contenidoid=41876 (21=)
21) Disposición ANMAT N° 3060 del 30 del marzo de 2017.
http://www.anmat.gov.ar/boletin_anmat/marzo_2017/Dispo_3060-17.pdf.